Status:
COMPLETED
Pedometer Activity Monitoring After ASCT
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Lymphoma
Myeloma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The trial assess the proportion of patients who resumed their professional activity within 100 days after ASCT (autologous stem cell Transplantation).
Detailed Description
Patient-reported outcome measures (PROMs) Cancer patients experience significant physical and psychosocial consequences of cancer and treatment which affect quality of life (QoL). These consequences m...
Eligibility Criteria
Inclusion
- Patients with plasma cell disorders (myeloma and amyloidosis) or with lymphomas (NHL and Hodgkin) undergoing high-dose chemotherapy with autologous stem cell transplantation.
- Patients must be aged 18-65 years.
- Patients must have given voluntary written informed consent.
- Patients without professional activity (such as due to early retirement, dependency on disability reimbursement, or unemployment) are eligible.
Exclusion
- Patients with other serious medical condition that could potentially interfere with the completion of treatment according to this protocol.
- Lack of patient cooperation to allow study treatment as outlined in this protocol.
Key Trial Info
Start Date :
November 2 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT03238599
Start Date
November 2 2017
End Date
March 1 2022
Last Update
April 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Departement of Medical Oncology, University Hospital Berne
Bern, Switzerland, 3010